Clinical trial
SIGA-246 to Treat Smallpox
NCT00303225 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Withdrawn
Key facts
| NCT number | NCT00303225 |
|---|---|
| Title | SIGA-246 to Treat Smallpox |
| Official title | A Double-Blind, Randomized, Placebo-Controlled, Ascending Single-Dose, Phase I Trial of the Anti-Orthopoxvirus Compound SIGA-246 in Healthy Volunteers |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Vaccinia |
| Intervention type | Drug |
| Interventions | Vaccine: SIGA-246 |
| Enrollment | 0 |
| Start date | Mar 13, 2006 |
| Completion | Aug 4, 2006 |
| First posted | Mar 15, 2006 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: